Application of polypeptide or fragment thereof in preparation of kit for detecting vascular endothelial cell injury

By contacting the patient's biological samples with polypeptide or its antibody binding fragments to form antigen-antibody complexes, the problem of diagnosis of vascular endothelial cell damage in the prior art is solved, simple and effective serum detection is achieved, and idiopathic nephrotic syndrome is improved The diagnostic sensitivity and specificity of the patient have great clinical application value.

CN118937668AActive Publication Date: 2024-11-12ZHEJIANG UNIV

Patent Information

Application Number
CN202410554458.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-03-02
Publication Date
2024-11-12
Estimated Expiration
2043-03-02

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and monitor vascular endothelial cell damage, especially in patients with idiopathic nephrotic syndrome (INS). Traditional methods such as electron microscopy are expensive and unsuitable for routine applications, and current clinical treatment cannot help all patients achieve remission. .

Method used

Develop polypeptides or antibody binding fragments thereof, including alpha enolase protein (ENO1), anklein 1 (TLN1), filament protein-A (FLNA), desmosomal ligand protein (AHNAK), desmosomal cordin-1 ( DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4) and membrane cross protein (MSN), are used to contact patient biological samples to form antigen-antibody complexes. Prepare a kit for detecting vascular endothelial cell damage.

Benefits of technology

Through simple serum detection, it can effectively diagnose vascular endothelial cell damage, significantly reduce the autoantibodies of vascular endothelial cells in INS patients, improve the diagnostic sensitivity and specificity, have great clinical application value, and can help diagnose idiopathic nephropathy. Syndrome and other related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937668A_ABST
    Figure CN118937668A_ABST
Patent Text Reader

Abstract

The invention relates to application of a polypeptide or an antibody binding fragment thereof capable of being in contact with a biological sample obtained from a patient to form an antigen-antibody complex in preparation of a vascular endothelial cell injury detection reagent or kit. Wherein the polypeptide or the antibody binding fragment thereof comprises at least two selected from the following groups: alpha enolase protein (ENO1), ankle protein 1 (TLN1), filament protein-A (FLNA), desmomere associative protein (AHNAK), desmomere core glycoprotein 1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90beta (HSP90AB1), cytoskeleton associated protein 4 (CKAP4) and moesin (MSN). The vascular endothelial cell autoantibody disclosed by the invention can be used for diagnosing vascular endothelial cell injury by simply detecting the titer in serum, and has a very great clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with application number 202310216552.5, application date March 2, 2023, and invention name "Application of polypeptides or fragments thereof in the preparation of a kit for detecting vascular endothelial cell damage." Technical Field

[0002] The present invention relates to the field of diagnostic kits, and in particular to the application of polypeptides or fragments thereof in the preparation of a kit for detecting vascular endothelial cell damage. Background Art

[0003] Idiopathic nephrotic syndrome (INS) is one of the most common primary glomerular diseases in children, with approximately 28,000 to 56,000 new cases in China each year. Steroid therapy is effective for most patients, but approximately 10% to 20% of patients are ineffective against steroid therapy, which is called steroid-resistant nephrotic syndrome (SRNS). Among patients with INS, 8% to 35% develop end-stage renal disease (ESRD) 5 years after diagnosis, and 24% to 66% develop ESRD 15 years after diagnosis. However, to date, the pathogenesis of INS has not been fully elucidated.

[0004] Minimal change disease (MCD) is the leading cause of nephrotic syndrome in children and accounts for 10-15% of nephrotic syndrome in adults. The glomeruli of patients with minimal change disease appear basically normal under light microscopy, and the only histopathological abnormality visible under electron microscopy is diffuse fusion and disappearance of podocyte foot processes. Therefore, a common view is that the pathogenesis of INS may be related to systemic dysfunction of T cells, and selective T cell inhibitors such as cyclosporine / tacrolimus are effective in some patients. In addition to T cells, circulating permeability factors such as soluble urokinase-type plasminogen activator receptor are also possible pathogenic factors. However, current clinical treatments based on the above theory cannot help all patients achieve clinical remission. Therefore, researchers have been exploring other possible pathological mechanisms. Summary of the invention

[0005] In view of the technical problems existing in the prior art, the present invention proposes the use of a polypeptide or an antibody binding fragment thereof that can contact with a biological sample obtained from the patient to form an antigen-antibody complex in the preparation of a vascular endothelial cell injury detection reagent or kit; wherein the polypeptide or its antibody binding fragment comprises at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0006] In some embodiments, the polypeptide or antibody binding fragment thereof is a combination of heat shock protein 90β (HSP90AB1) and cytoskeleton-associated protein 4 (CKAP4), or a combination of talin 1 (TLN1) and desmoglein 1 (DSG1), or a combination of talin 1 (TLN1) and moesin (MSN).

[0007] In some embodiments, wherein the vascular endothelial cell damage is indicative of nephrotic syndrome.

[0008] In some embodiments, wherein the nephrotic syndrome is idiopathic nephrotic syndrome.

[0009] In some embodiments, wherein the idiopathic nephrotic syndrome is childhood idiopathic nephrotic syndrome.

[0010] In some embodiments, the biological sample is serum.

[0011] In some embodiments, the biological sample is a biological sample of a patient before immunotherapy.

[0012] In some embodiments, the present invention also proposes the use of a polypeptide or an antibody binding fragment thereof that can contact with a biological sample obtained from the patient to form an antigen-antibody complex in the preparation of a vascular endothelial cell injury detection reagent or kit; wherein the polypeptide or its antibody binding fragment includes at least three selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0013] In some embodiments, the polypeptide or its antibody binding fragment is a combination of desmoglein 1 (DSG1), moesin (MSN) and talin 1 (TLN1), or a combination of moesin (MSN), myosin light chain 1 (MYL1) and talin 1 (TLN1), or a combination of alpha enolase ENO1, talin 1 (TLN1) and heat shock protein 90β (HSP90AB1).

[0014] In some embodiments, the present invention also proposes the use of a polypeptide or antibody binding fragment capable of forming any antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a reagent or kit for specifically detecting nephrotic syndrome relative to purpura nephritis, Henoch-Schönlein purpura, and Kawasaki disease; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nephrin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0015] In some embodiments, the present invention also proposes a reagent or kit for diagnosing nephrotic syndrome or specifically detecting nephrotic syndrome relative to purpura nephritis, Henoch-Schönlein purpura, and Kawasaki disease, comprising: a polypeptide or an antibody binding fragment thereof, which is capable of contacting with a biological sample obtained from the patient to form any antigen-antibody complex; wherein the polypeptide or its antibody binding fragment comprises at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nephrin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0016] The gold standard for endothelial cell injury is electron microscopy. However, electron microscopy requires renal puncture, which is damaging and expensive, takes a long time to detect, and is not suitable for routine application. The endothelial cell autoantibodies of the present application can be used to diagnose endothelial cell injury by simply detecting the titer in serum, and have great clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The preferred embodiments of the present invention will be further described in detail below with reference to the accompanying drawings, wherein:

[0018] FIG. 1 is a diagram of endothelial cell autoantibody detection according to an embodiment of the present invention; Figures 1A-1IThe detection of endothelial cell autoantibodies in INS patients and other control group participants according to one embodiment of the present application; NC represents a normal control group; HSP represents Henoch-Schonlein purpura; HSPN represents Henoch-Schonlein purpura nephritis; KD represents Kawasaki disease; NS represents nephrotic syndrome; Figure 1J-1K It shows the changing pattern of endothelial cell autoantibodies in INS patients according to one embodiment of the present application;

[0019] FIG. 2 shows the diagnostic value of 9 endothelial cell autoantibodies in INS according to an embodiment of the present invention; wherein, Figure 2A is a ROC curve of an anti-ENO1 antibody according to one embodiment of the present application; Figure 2B is a ROC curve of an anti-TLN1 antibody according to one embodiment of the present application; Figure 2C is a ROC curve of an anti-FLNA antibody according to one embodiment of the present application; Figure 2D is a ROC curve of an anti-AHNAK antibody according to one embodiment of the present application; Figure 2E is a ROC curve of an anti-DSG1 antibody according to one embodiment of the present application; Figure 2F is a ROC curve of an anti-MYL1 antibody according to one embodiment of the present application; Figure 2G is a ROC curve of an anti-HSP90AB1 antibody according to one embodiment of the present application; Figure 2H is a ROC curve of an anti-CKAP4 antibody according to one embodiment of the present application; Fig.2I is a ROC curve of an anti-MSN antibody according to one embodiment of the present application;

[0020] FIG3 is a graph showing the correlation between the grayscale value of endothelial cell autoantibodies and the clinical condition of INS patients according to an embodiment of the present invention; wherein, Figure 3A According to one embodiment of the present application, compared with before remission, 9 vascular endothelial cell autoantibodies were significantly reduced after remission; Figure 3B For INS patients according to one embodiment of the present application, the first seven vascular endothelial cell autoantibodies are significantly negatively correlated with serum albumin; Figure 3C According to one embodiment of the present application, 8 vascular endothelial cell autoantibodies are significantly negatively correlated with the international normalized ratio (INR) of INS patients before remission; Figure 3D According to one embodiment of the present application, 7 vascular endothelial cell autoantibodies are significantly negatively correlated with the platelet count of INS patients before remission;

[0021] FIG4 is a diagram of renal endothelial injury in an INS patient according to an embodiment of the present invention; wherein, Figure 4A- Figure 4G According to one embodiment of the present application, 7 typical signs of endothelial damage in renal biopsy specimens of INS patients were observed under an electron microscope; Figure 4HThe pattern of different signs of endothelial injury in 20 INS patients according to one embodiment of the present application; Fig. 4I Immunofluorescence of human kidney according to one embodiment of the present application shows upregulation of caveolin-1 (green) and co-localization with EHD3 (red);

[0022] FIG5 is a diagram showing the effect of an anti-ENO1 antibody in vitro according to an embodiment of the present invention; wherein, Figure 5A-5C The actin skeleton changes and separation of Eahy926 cells after pretreatment with ENO1 protein by isotype control antibody and anti-ENO1 antibody, isotype control antibody and normal rabbit serum and anti-ENO1 antibody and normal rabbit serum, anti-ENO1 antibody positive serum and anti-ENO1 antibody positive serum according to one embodiment of the present application; Figure 5D-5F The difference between the level of thrombomodulin in the supernatant of Eahy926 cells treated with isotype control antibody according to one embodiment of the present application and anti-ENO1 antibody, isotype control antibody normal rabbit serum and anti-ENO1 antibody normal rabbit serum, anti-ENO1 antibody serum and anti-ENO1 serum pretreated with ENO1 protein;

[0023] Figure 6 The figure is the histology (HE staining, PAS staining and Masson staining) of mouse kidney injected with antibody according to one embodiment of the present invention;

[0024] Figure 7 According to an embodiment of the present invention, damage to endothelial cells and podocytes of mice injected with anti-ENO1 antibodies can be seen under an electron microscope; wherein, Figure 7 A shows that autophagosomes can be observed in the glomerular endothelial cells of mice injected with anti-ENO1 antibodies according to one embodiment of the present application; Figure 7 B shows that mitochondrial damage can be observed in the podocytes of mice treated with an anti-ENO1 antibody according to one embodiment of the present application; Figure 7 C- Figure 7 D is that the podocytes of the anti-ENO1 antibody-injected mice according to one embodiment of the present application can be observed to have fused foot processes, but the podocytes of the isotype antibody-injected mice have not; and

[0025] FIG8 is a graph showing sensitivity and specificity when one or more antibodies are used in combination according to an embodiment of the present invention; Figure 8A-8I is the sensitivity and specificity profile of the antibody when used alone; Figure 8J-Figure 8M It is the sensitivity and specificity profile when two antibodies are used in combination; Figure 8N-Figure 8Q The sensitivity and specificity profiles of the three antibodies when used in combination. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] In the following detailed description, reference may be made to the various specification drawings that are part of the present application and are used to illustrate specific embodiments of the present application. In the accompanying drawings, similar reference numerals describe substantially similar components in different figures. The various specific embodiments of the present application are described below in sufficient detail so that a person of ordinary skill in the art with relevant knowledge and skills in the art can implement the technical solutions of the present application. It should be understood that other embodiments may also be used or structural, logical or electrical changes may be made to the embodiments of the present application.

[0028] The nouns used in this article have the following meanings:

[0029] The "nephrotic syndrome" or "NS" mentioned in this article refers to a clinical syndrome characterized by a series of pathophysiological changes caused by increased permeability of the glomerular filtration membrane to plasma proteins and the loss of large amounts of plasma proteins in the urine, with massive proteinuria, hypoproteinemia, hyperlipidemia and edema as its main clinical features.

[0030] The "idiopathic nephrotic syndrome" or "INS" mentioned in this article is a type of disease with unknown etiology. Due to the increased permeability of the glomerular filtration membrane, the filtration of plasma proteins increases, causing massive proteinuria, which in turn triggers a series of clinical syndromes characterized by podocyte lesions. Children with this type of disease often show clinical symptoms such as massive proteinuria, hypoproteinemia, edema, and hyperlipidemia.

[0031] The "polypeptide or its fragment" mentioned in this article refers to a combination of two or more polypeptide indicators used to detect the same disease. Among them, the polypeptide or its antibody binding fragment is selected from: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane spike protein (MSN).

[0032] Among them, the sequence of the antibody binding fragment of alpha enolase protein (ENO1) is shown in SEQ ID NO.1; the sequence of the antibody binding fragment of talin 1 (TLN1) is shown in SEQ ID NO.2; the sequence of the antibody binding fragment of filament protein-A (FLNA) is shown in SEQ ID NO.3; the sequence of the antibody binding fragment of desmosome annexin (AHNAK) is shown in SEQ ID NO.4; the sequence of the antibody binding fragment of desmoglein-1 (DSG1) is shown in SEQ ID NO.5; the sequence of the antibody binding fragment of myosin light chain 1 (MYL1) is shown in SEQ ID NO.6; the sequence of the antibody binding fragment of heat shock protein 90β (HSP90AB1) is shown in SEQ ID NO.7; the sequence of the antibody binding fragment of cytoskeleton-associated protein 4 (CKAP4) is shown in SEQ ID NO.8; the sequence of the antibody binding fragment of membrane spike protein (MSN) is shown in SEQ ID NO.9.

[0033] When the above polypeptide or its antibody binding fragment is used to detect vascular endothelial cell damage, it can be contacted with a biological sample obtained from a patient to form an antigen-antibody complex, wherein the antigen-antibody complex includes an anti-ENO1-IgG antibody complex, an anti-TLN1-IgG antibody complex, an anti-FLNA-IgG antibody complex, an anti-AHNAK-IgG antibody complex, an anti-DSG1-IgG antibody complex, an anti-MYL1-IgG antibody complex, an anti-HSP90AB1-IgG antibody complex, an anti-CKAP4-IgG antibody complex, and an anti-MSN-IgG antibody complex.

[0034] The "isotype control antibody" mentioned in this article refers to the IgG antibody extracted from the serum of rabbits of the same breed and age that have not been immunized with protein, used as a control group.

[0035] The "HE staining" mentioned in this article refers to hematoxylin-eosin staining, also known as HE staining, which is one of the commonly used staining methods in paraffin section technology. Hematoxylin staining is alkaline, which mainly stains the chromatin in the cell nucleus and the nucleic acid in the cytoplasm purple-blue; eosin is an acidic dye, which mainly stains the components in the cytoplasm and extracellular matrix red.

[0036] The "Masson staining" mentioned in this article is also called Masson staining. It is one of the main methods for displaying fibers in tissues and is an authoritative and classic technical method for collagen fiber staining. The staining principle of this method is related to the size of anionic dye molecules and the penetration of tissues. The size of molecules is reflected by molecular weight. Small molecular weight can easily penetrate densely structured and low permeability tissues; while large molecular weight can only enter loosely structured and high permeability tissues. However, the molecular weight of light green or aniline blue is very large, so after Masson staining, muscle fibers appear red and collagen fibers appear green or blue. It is mainly used to distinguish collagen fibers from muscle fibers.

[0037] The "PAS stain" mentioned in this article refers to Periodic Acid-Schiff stain, also known as periodic acid-Schiff stain. In histology, it is mainly used to detect sugars in tissues. Periodic acid oxidizes the hydroxyl groups on the two adjacent carbons of sugars into aldehyde groups, and then uses Schiff reagent to react with the aldehyde groups to make them appear purple-red. PAS positive is red, and the cell nucleus is blue.

[0038] In 2021, the inventor team first proposed the concept of autoimmune podocytosis, which has been widely recognized. Recently, Watts et al. found anti-glomerular cell adhesion molecule receptor (Nephrin) autoantibodies in the serum of children and adult MCD patients, which also provided strong evidence for the inventor's innovative theory. In addition, the presence of anti-renin autoantibodies in the serum of patients with focal segmental glomerulosclerosis (FSGS) after transplantation further supports the inventor's point of view. The new idiopathic nephrotic syndrome mouse model induced by immunization with the podocyte protein Crb2 provides direct evidence for the role of podocyte autoantibodies in the pathogenesis of INS.

[0039] Podocyte autoantibodies are considered to be an important cause of glomerular podocyte damage. However, from an anatomical point of view, there is a glomerular endothelial barrier between circulating podocyte autoantibodies and podocytes. Unless the integrity of the glomerular endothelial cells is damaged, podocyte autoantibodies cannot reach the podocytes.

[0040] The inventors have found through a series of experiments that there are multiple anti-endothelial cell autoantibodies in the serum of children with INS. Anti-endothelial cell autoantibodies cause glomerular endothelial cell damage, thereby causing the destruction of the endothelial barrier between circulating podocyte autoantibodies and podocytes. This is an important cause of glomerular endothelial cell damage. The multiple anti-endothelial cell autoantibodies and their combinations discovered by the inventors can be used to diagnose endothelial cell damage and further diagnose INS.

[0041] The present application proposes the use of a polypeptide or its antibody binding fragment that can contact with a biological sample obtained from the patient to form an antigen-antibody complex in the preparation of a vascular endothelial cell injury detection reagent or kit; wherein the polypeptide or its antibody binding fragment is selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0042] In some embodiments, any one of the above 9 polypeptides or antibody binding fragments can be used alone to detect vascular endothelial cell damage. In some embodiments, at least two of the above 9 polypeptides or antibody binding fragments can also be used in combination.

[0043] Furthermore, in some embodiments, when two of the above 9 polypeptides or antibody binding fragments are used in combination, the sensitivity is the highest when talin 1 (TLN1) and desmoglein 1 (DSG1) are combined, reaching 88.2; the sensitivity is slightly lower when filament protein A (FLNA) and desmoglein 1 (DSG1) are combined, which is 70.6. When any two of the other 9 polypeptides or antibody binding fragments are combined, the sensitivity is between the two, which are not listed here. In addition, in some embodiments, when talin 1 (TLN1) and moesin (MSN) are used in combination, the specificity is the highest, reaching 85.7, and the specificity of any other two combinations is also above 57.1.

[0044] In some embodiments, when three of the above-mentioned 9 polypeptides or antibody binding fragments are used in combination, the combination of desmoglein 1 (DSG1), moesin (MSN) and talin 1 (TLN1), or the combination of moesin (MSN), myosin light chain 1 (MYL1) and talin 1 (TLN1) has a higher sensitivity of 76.5; when cytoskeleton-associated protein 4 (CKAP4), desmoglein 1 (DSG1) and filament protein A (FLNA) are used in combination, the sensitivity is slightly lower, at 64.7; when any three of the other 9 polypeptides or antibody binding fragments are used in combination, the sensitivity is between the two, which are not listed here. In addition, in some embodiments, when the combination of desmoglein 1 (DSG1), moesin (MSN) and talin 1 (TLN1), or the combination of moesin (MSN), myosin light chain 1 (MYL1) and talin 1 (TLN1) is used, the specificity is the highest, reaching 85.7, and the specificity of any other three combinations is also above 64.3.

[0045] In some embodiments, when a combination of at least four of the above nine polypeptides or antibody binding fragments is used, the combination basically includes the two-by-two combinations or three-way combinations listed in this application and are not listed here.

[0046] The present application further proposes the use of a polypeptide or antibody binding fragment that can form any antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a reagent or kit for the specific detection of nephrotic syndrome relative to purpura nephritis, Henoch-Schönlein purpura, and Kawasaki disease; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nephrin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0047] The present application further proposes a reagent or kit for diagnosing nephrotic syndrome or specifically detecting nephrotic syndrome relative to purpura nephritis, Henoch-Schönlein purpura, and Kawasaki disease, comprising: a polypeptide or an antibody binding fragment thereof, which is capable of contacting with a biological sample obtained from the patient to form any antigen-antibody complex; wherein the polypeptide or its antibody binding fragment comprises at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nephrin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), and membrane spike protein (MSN).

[0048] In some embodiments, the polypeptide or antibody binding fragment described in the present application is expressed in vascular endothelial cells, and the titer of the antibody complex can indicate vascular endothelial cell damage. Further, the indication of vascular endothelial cell damage can indicate nephrotic syndrome. In some embodiments, the nephrotic syndrome is idiopathic nephrotic syndrome. Further, the idiopathic nephrotic syndrome is idiopathic nephrotic syndrome in children.

[0049] In some embodiments, when one or more of the above 9 polypeptides or antibody binding fragments thereof are used to detect vascular endothelial cell damage, a biological sample of the patient is first obtained, and the biological sample can be the patient's serum, and the biological sample is the patient's biological sample before immunotherapy. In some embodiments, the titer of the antigen-antibody complex in the biological sample can be detected to detect vascular endothelial cell damage, and further detect nephrotic syndrome.

[0050] The present application will illustrate the invention content through the following examples. In this application, a total of 149 INS patients were recruited, and the control group was divided into 4 groups: Group 1 consisted of 100 healthy children (normal controls, NC) undergoing physical examinations, and the other 3 groups consisted of 100 children each with other vasculitis-related diseases such as Henoch-Schonlein purpura (HSP), Henoch-Schonlein purpura nephritis (HSPN), and Kawasaki disease (KD). The children's serum was collected and stored at -20°C until use.

[0051] Example 1: Detection of serum endothelial autoantibodies in children with INS and control group

[0052] Protein microarray was used to detect the titer of endothelial cell autoantibodies in the serum of INS patients and control group participants. The production and use of protein microarray followed the following description:

[0053] Cell culture and protein extraction: The HUVEC-derived cell line EAhy926 was purchased from the Cell Bank of the Chinese Academy of Sciences. Eahy926 cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Eahy926 cells were then washed with sterile PBS, harvested, and incubated on ice with 30 mm Tris-HCl, 8 M urea, 4% CHAPS, and protease inhibitor cocktail (#ab65621; Abcam, diluted 1:200). Next, the samples were centrifuged at 12,000 g for 30 minutes at 4 degrees Celsius. The supernatant was then collected for later use. The total protein concentration was determined using a bicinchoninic acid (BCA) protein concentration assay kit (Pierce TM , Thermo) determination.

[0054] Two-dimensional electrophoresis and immunoblotting: Two-dimensional electrophoresis was performed using a 2D electrophoresis system (etan TM IPGphor 3 TM , GE Healthcare) were subjected to two-dimensional electrophoresis of EAhy926 protein extracts. 25 μl of total protein (100 μg) were loaded into 13 cm, pH 3-10 IPG strips (GE Healthcare) for isoelectric focusing as one-dimensional electrophoresis. The gel strips obtained from the one-dimensional electrophoresis were further separated by SDS electrophoresis in the second dimension. The separated proteins were electrophoretically transferred to PVDF membranes. The blocked cell membranes were incubated overnight at 4°C with 1:200 diluted serum, 20 of which were from patients with nephrotic syndrome and 10 from healthy controls. Incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies was followed by incubation with enhanced chemiluminescence detection reagents. Finally, the membranes were imaged using a Bio-Rad imager and analyzed using PD Quest software.

[0055] Briefly, autoantigens were labeled on nitrocellulose membranes and blocked with bovine serum albumin sealing solution. After being fixed in the slots of polyvinyl chloride detection plates, serum was added to the detection plates. After washing, detection was performed with biotin-conjugated anti-human IgG. The arrays were cleaned and developed using 5-bromo-4-chloro-3-indoleyl phosphate (BCIP) / nitro blue tetrazolium chloride (NBT) substrates and scanned at 2400 dpi using a flatbed scanner (canscan 9000Mark II, Canon).

[0056] As Figure 1A-Figure 1I As shown in Figure 2, the concentrations of 9 endothelial cell autoantibodies in INS patients were higher than those in the control group. Figure 1J The results showed that in patients with INS, the positive rate of anti-ENO1 antibodies was the highest (51.01%), and the positive rates of other identified endothelial cell autoantibodies were as follows: talin-1 endothelial cell autoantibodies (anti-TLN1 antibodies), 50.34%; filament-A endothelial cell autoantibodies (anti-FLNA antibodies), 48.32%; desmosome nexin (anti-AHNAK antibodies), 45.64%; desmoglein-1 endothelial cell autoantibodies (anti-FLNA antibodies), 48.32%; desmoglein-2 endothelial cell autoantibodies (anti-AHNAK antibodies), 45.64%; desmoglein-3 endothelial cell autoantibodies (anti-FLNA antibodies), 48.32%; desmoglein-4 endothelial cell autoantibodies (anti- Autoantibodies (anti-DSG1 antibodies), 42.95%; myosin light chain 1 endothelial cell autoantibodies (anti-MYL1 antibodies), 42.28%; heat shock protein 90-β endothelial cell autoantibodies (anti-HSP90AB1 antibodies), 40.27%; cytoskeleton-associated protein 4 endothelial cell autoantibodies (anti-CKAP4 antibodies), 38.93%; membrane protrusion protein endothelial cell autoantibodies (anti-MSN antibodies), 31.54%. Figure 1K As shown in Figure 2, only 11% of all INS patients were negative for all nine endothelial autoantibodies. In other words, 89% of INS patients in this study were positive for at least one endothelial autoantibody.

[0057] Then, the inventors performed ROC analysis on the grayscale values ​​of endothelial cell autoantibodies in the serum of INS patients and control subjects, and calculated the area under the ROC curve (ROC-auc). The results showed that all 9 identified endothelial autoantibodies could easily distinguish INS patients from the control group, and their AUCs were all greater than 0.7 (Figure 2). Among them, the ROC curve of α-enolase endothelial cell autoantibodies (anti-ENO1 antibodies) showed the strongest distinction between INS patients and the control group (AUC was 0.806).

[0058] Example 2: Circulating endothelial autoantibodies are associated with the condition and coagulation function of INS patients

[0059] In vivo pathogenicity detection of endothelial cell autoantibodies: The inventors studied the pathogenicity of anti-ENO1 antibodies by tail vein injection into BALB / c mice (n=5). To control for the short half-life of the injected isotype antibodies, anti-ENO1 antibodies were injected twice at 24-hour intervals at 200 μg of each antibody. The development of proteinuria was monitored every 24 hours using metabolic cages for 7 days. Five BALB / c mice were injected with isotype control IgG at the same dose as the control group. Kidneys were harvested on day 7. Tissue sections (5 μm thick) were prepared and histologically evaluated for tissue morphology, damage, and fibrosis using hematoxylin and eosin (H&E), periodic acid-Schiff staining (PAS), or Masson's trichrome staining. Electron microscopy analysis was performed according to standard procedures. Kidneys were fixed in 4% buffered paraformaldehyde, followed by 1% osmium acid in 0.1 M sodium carbonate buffer, then stained with 1% uranyl acetate and embedded in epoxy resin. Ultrathin sections were cut and contrasted with uranyl acetate in methanol and then with lead citrate. Micrographs were generated using a transmission electron microscope.

[0060] In vitro pathogenicity detection of endothelial cell autoantibodies: The inventors detected the in vitro pathogenicity of endothelial cell autoantibodies by three comparative methods. The first comparison was to treat EAhy926 cells with anti-ENO1 antibody or rabbit isotype IgG for 2 hours, and untreated cells were used as blank controls. The morphology of Eahy926 cells was observed under a light microscope. The actin skeleton was visible by intracellular penis staining. Cell apoptosis detection was performed using a commercially available kit (#556547, BD Biosciences). For comparison, EAhy926 cells were treated with rabbit serum or rabbit serum and anti-ENO1 antibody, respectively. For comparison, anti-ENO1 antibody-positive serum from INS patients was first mixed with the corresponding recombinant protein in a humidified incubator at 37°C for 30 minutes. EAhy926 cells were then treated with endothelial cell autoantibody-positive serum from INS patients or serum-recombinant protein complexes. The latter two comparative methods detected the cell morphology after treatment, the structural changes of the cytoskeletal protein F-actin, and the level of thrombomodulin in the culture supernatant.

[0061] Statistical analysis: Normally distributed measurements were expressed as mean ± standard deviation, and non-normally distributed measurements were expressed as median and interquartile range. For paired comparisons, we used paired t-test or Wilcoxon paired signed rank test. Linear regression and Pearson coefficient were used to characterize the correlation between endothelial cell autoantibodies and other variables. P < 0.05 was defined as statistically significant. All statistical analyses were performed using GraphPad Prism version 9.0 software.

[0062] Comparison of endothelial cell autoantibody levels in INS patients at different disease states (before and after remission) to confirm endothelial damage in INS patients. Figure 3A As shown in Table 1, all 9 endothelial cell autoantibodies decreased significantly after remission. Hypercoagulation is often observed in INS patients. Therefore, the inventors conducted a correlation analysis between the titers of circulating endothelial autoantibodies and coagulation function-related laboratory test results in INS patients before remission. Figure 3B As shown in Figure 2, in patients with INS, 7 endothelial cell autoantibodies were significantly negatively correlated with serum albumin and INR, among which anti-CKAP4 antibody was best correlated with albumin (R=-0.42, p<0.001); Figure 3C As shown in Figure 2, anti-MYL1 antibodies were most correlated with INR (R = -0.30, p = 0.004). Figure 3D As shown, 8 endothelial cell autoantibodies were significantly positively correlated with the platelet count in patients with INS, among which anti-DSG1 antibody had the best correlation with the platelet count (R=0.37, p<0.001).

[0063] Table 1 Characteristics of subjects

[0064]

[0065]

[0066] Example 3: Kidneys of INS patients show signs of glomerular endothelial damage

[0067] To confirm whether INS patients have glomerular endothelial damage, the inventors performed electron microscopy focused on the endothelium in renal biopsy samples from 20 patients. Figure 4A- Figure 4G As shown in the figure, a total of 7 signs of endothelial injury were observed, including endothelial cell proliferation (Figure 4A), immune complex deposition (under the endothelium) (Figure 4B), endothelial cell swelling or vacuolar degeneration (Figure 4C), widening of the endothelial cell gap (Figure 4D), endothelial cell mitochondrial swelling (Figure 4E), honeycomb structure (Figure 4F), and loss of endothelial cell permeability (Figure 4F). Figure 4G In the present invention, endothelial cell swelling or vacuolar degeneration, mitochondrial swelling are the most common signs of glomerular endothelial injury, and the positive rate of each sign is 85% (eg Figure 4H It is worth noting that Fig. 4I As shown, in addition to endothelial fenestration fusion, all 20 INS patients showed at least one other sign of glomerular endothelial injury. Immunofluorescence of human renal tissue also showed signs of endothelial injury, with upregulation of caveolin-1 expression.

[0068] Example 4: Effect of anti-ENO1 antibody on EAhy926 cells

[0069] In order to determine whether endothelial cell autoantibodies have a pathogenic effect, the inventors tested the effect of anti-ENO1 antibodies on EAhy926 cells, because the anti-ENO1 antibody in the present invention has the highest positive rate in INS patients. Figure 5A-5D As shown, anti-ENO1 antibody-treated EAhy926 cells had a higher detachment rate compared to cells treated with isotype control antibody, and cytoskeletal disruption was manifested by the disappearance of actin-stress fibers rather than higher levels of thrombomodulin. Figure 5E As shown in Figure 2, the level of thrombomodulin in the supernatant of EAhy926 cells treated with normal rabbit serum and anti-ENO1 antibody was significantly higher than that in normal rabbit serum and isotype control antibody. Fig. 5F As shown, the concentration of thrombomodulin in the cell culture supernatant was significantly lower in the anti-ENO1 antibody + serum treated with ENO1 recombinant protein than in the untreated serum. This damage caused by the antibody can be enhanced in the presence of serum and can be weakened by pre-incubating the antibody with the corresponding recombinant protein.

[0070] Example 5: Injection of identified endothelial autoantibodies can cause endothelial cell and podocyte damage in BALB / c mice

[0071] like Figure 6 As shown in the figure, BALB / c mice were injected with anti-ENO1 antibodies. HE staining, Masson staining, and PAS staining did not show obvious pathological changes in the kidneys of the antibody-injected mice. However, autophagosomes were observed in the glomerular endothelial cells of mice, indicating that the recognized endothelial autoantibodies may cause damage to the glomerular endothelial cells (e.g. Figure 7 A- Figure 7 D). Figure 7 A- Figure 7 As shown in (D), in addition to the autophagosomes observed in glomerular endothelial cells, podocytes also showed signs of damage, with both SEM and TEM showing partial fusion of foot processes; in addition, some changes in mitochondria could be observed, including irregular shape, vacuolization, and cristae breakage.

[0072] Example 6: Diagnostic efficiency of endothelial autoantibodies in serum of INS patients for endothelial cell damage

[0073] The applicant fixed the potential autoantigen proteins obtained by screening on a protein chip, used the serum of patients with nephrotic syndrome as the primary antibody, and read the results through a scanner after incubation with secondary antibodies, enzyme working solution, and substrate solution to obtain the grayscale value corresponding to each antigen protein on the protein chip. The grayscale value is the relative content of autoantibodies in the serum. According to the presence or absence of endothelial cell damage under the electron microscope of renal tissue sections of INS patients, INS patients were divided into endothelial cell damage group and endothelial cell non-damage group. ROC analysis was performed based on the concentration of endothelial cell autoantibodies in serum to obtain AUC value, sensitivity and specificity.

[0074] like Figure 8A-8Q As shown in Table 2, the inventors performed ROC analysis on the grayscale values ​​of endothelial cell autoantibodies in the serum of INS patients and control subjects, and calculated the area under the ROC curve (ROC-auc). Figure 8A-8Q As shown in the figure, all 9 identified peptides, whether used alone or in combination of two or more of them, can easily diagnose INS patients, and their AUCs are all greater than 0.5. Among them, the ROC curves of the combination of desmoglein 1 + moesin + talin 1, the combination of α-enolase + talin 1 + heat shock protein 90β, the combination of moesin + myosin light chain 1 + talin 1, or the combination of talin 1 + desmoglein 1 have higher diagnostic efficiency among INS patients, with the highest AUC of 0.811.

[0075] Table 2

[0076]

[0077] The above embodiments are only used to illustrate the present invention, but not to limit the present invention. Ordinary technicians in the relevant technical field can make various changes and modifications without departing from the scope of the present invention. Therefore, all equivalent technical solutions should also fall within the scope of the present invention.

Claims

1. Use of a polypeptide or an antibody binding fragment thereof that can contact with a biological sample obtained from the patient to form an antigen-antibody complex in the preparation of a reagent or kit for detecting vascular endothelial cell damage; The polypeptide or antibody binding fragment thereof is a combination of talin 1 (TLN1) and moesin (MSN).

2. The use according to claim 1, wherein the vascular endothelial cell damage indicates nephrotic syndrome.

3. The use according to claim 1, wherein the nephrotic syndrome is idiopathic nephrotic syndrome.

4. The use according to claim 3, wherein the idiopathic nephrotic syndrome is childhood idiopathic nephrotic syndrome.

5. The use according to claim 1, wherein the biological sample is serum. The use according to claim 1 , wherein the biological sample is a biological sample of a patient before immunotherapy.

7. Use of a polypeptide or antibody binding fragment capable of forming any antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a reagent or kit for specifically detecting nephrotic syndrome relative to purpura nephritis, Henoch-Schonlein purpura, and Kawasaki disease; The polypeptide or antibody binding fragment thereof is a combination of talin 1 (TLN1) and moesin (MSN).

8. A reagent or kit for diagnosing nephrotic syndrome or specifically detecting nephrotic syndrome relative to purpura nephritis, Henoch-Schonlein purpura, or Kawasaki disease, include: a polypeptide or an antibody-binding fragment thereof, which is capable of forming any antigen-antibody complex in contact with a biological sample obtained from said patient; The polypeptide or antibody binding fragment thereof is a combination of talin 1 (TLN1) and moesin (MSN).

Citation Information

Patent Citations

  • Probe set and kit for detecting whole exons of extended genetic diseases and application of probe set

    CN110499364A

  • Application of reagent for detecting anti-moesin-IgG antibody in preparation of kit for detecting vascular endothelial injury

    CN114910650A

  • Apparatuses and methods for detection of pancreatic cancer

    US20220397576A1

Cited By

  • Application of polypeptide or fragment thereof in preparation of kit for detecting vascular endothelial cell injury

    CN118258997A

  • Use of polypeptides or fragments thereof in the preparation of a kit for detecting vascular endothelial cell damage

    CN118258997B